{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '10.8.2.1. Permitted Concomitant Medication', 'Patients will receive concomitant medications to treat symptoms, AEs, and intercurrent illnesses', 'that are medically necessary as part of standard care. Medications to treat concomitant diseases', 'like diabetes, hypertension, etc. are allowed.', '10.8.2.2. Use of Blood Products', 'During treatment, patients may receive RBC or platelet transfusions, if clinically indicated, per', 'institutional guidelines. Patients who require repeated transfusion support should be discussed', 'with the Sponsor.', 'Appropriate anti-coagulation is allowed during the study (eg, low molecular weight heparin,', 'direct factor Xa inhibitors, etc.). Warfarin is allowed during the study provided patients are', 'monitored for INR twice a week during the first 2 cycles of study treatment, then weekly to', 'biweekly thereafter.', 'Patients may receive supportive care with erythropoietin, darbepoetin, G-CSF or GM-CSF,', 'pegylated growth factors, and platelet stimulatory factors, in accordance with clinical practice or', 'institutional guidelines throughout the study.', 'The use of blood products, transfusions, etc. will be documented in the eCRF.', '10.8.2.3. Radiation Treatment', 'If clinically indicated, palliative radiation therapy to non-target lesions is permitted but study', 'treatment should be held for >1 day before the start of palliative radiation therapy and >1 day', 'following each dose of palliative radiation therapy. Study treatment shall not be discontinued', 'solely due to palliative radiation.', '10.8.3.', 'Restrictions for Study Treatment', '10.8.3.1. Restrictions for Selinexor', 'Medications: There are no restrictions on the use of acetaminophen or acetaminophen-', 'containing products in combination with selinexor, EXCEPT on days of selinexor', 'dosing, when acetaminophen use must not exceed a total daily dose of 1 g.', 'Patients should not take GSH-, S-adenosylmethionine (SAM)- or', 'N-acetylcysteine-containing products during their participation in this study as', 'these products may enhance the metabolism of selinexor. However, they are', 'permitted if the patient has elevated liver function tests.', 'Diet:', 'There are no dietary restrictions on this study. Patients on selinexor should', 'maintain adequate caloric and fluid intake.', '10.8.3.2. Restrictions for Bortezomib and Dexamethasone', 'Refer to the full prescribing information for bortezomib (different local/regional trade names', 'may be used) for the most current information for restrictions.', 'Confidential', 'Page 71', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '10.8.4.', 'Prohibited Medications', 'Concurrent therapy with any approved or investigative anticancer therapeutic outside of those', 'included in this study is not allowed. Use of any immunosuppressive agents during the study', 'must be confirmed by the Sponsor. Refer to the full prescribing information for bortezomib', '(different local/regional trade names may be used) for the most current information on prohibited', 'concurrent medications.', 'Confidential', 'Page 72', 'Version 4.0']\n\n###\n\n", "completion": "END"}